Literature DB >> 32343812

From inflammation to cancer: entering a new frontier in the management of Erdheim-Chester disease.

Lakshmi Nayak1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32343812      PMCID: PMC7339893          DOI: 10.1093/neuonc/noaa110

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

1.  Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).

Authors:  Fleur Cohen Aubart; Jean-François Emile; Fabrice Carrat; Frédéric Charlotte; Neila Benameur; Jean Donadieu; Philippe Maksud; Ahmed Idbaih; Stéphane Barete; Khê Hoang-Xuan; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2017-06-30       Impact factor: 22.113

2.  CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.

Authors:  Laurent Arnaud; Baptiste Hervier; Antoine Néel; Mohamed A Hamidou; Jean-Emmanuel Kahn; Bertrand Wechsler; Gemma Pérez-Pastor; Bjørn Blomberg; Jean-Gabriel Fuzibet; François Dubourguet; António Marinho; Catherine Magnette; Violaine Noel; Michel Pavic; Jochen Casper; Anne-Bérangère Beucher; Nathalie Costedoat-Chalumeau; Laurent Aaron; Juan Salvatierra; Carlos Graux; Patrice Cacoub; Véronique Delcey; Claudia Dechant; Pascal Bindi; Christiane Herbaut; Giorgio Graziani; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

Review 3.  Erdheim-Chester Disease: a Concise Review.

Authors:  Matthias Papo; Jean-François Emile; Thiago Trovati Maciel; Pierre Bay; Alistair Baber; Olivier Hermine; Zahir Amoura; Julien Haroche
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

4.  Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Authors:  Filip Janku; Eli L Diamond; Aaron M Goodman; Vaijayanthi Kandadai Raghavan; Tamara G Barnes; Shumei Kato; Omar Abdel-Wahab; Benjamin H Durham; Funda Meric-Bernstam; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

5.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

6.  Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.

Authors:  Gaurav Goyal; Mark L Heaney; Matthew Collin; Fleur Cohen-Aubart; Augusto Vaglio; Benjamin H Durham; Oshrat Hershkovitz-Rokah; Michael Girschikofsky; Eric D Jacobsen; Kazuhiro Toyama; Aaron M Goodman; Paul Hendrie; Xin-Xin Cao; Juvianee I Estrada-Veras; Ofer Shpilberg; André Abdo; Mineo Kurokawa; Lorenzo Dagna; Kenneth L McClain; Roei D Mazor; Jennifer Picarsic; Filip Janku; Ronald S Go; Julien Haroche; Eli L Diamond
Journal:  Blood       Date:  2020-05-28       Impact factor: 22.113

7.  Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Julien Haroche; Zhan Yao; Jing Ma; Sameer A Parikh; Zhaoming Wang; John Choi; Eunhee Kim; Fleur Cohen-Aubart; Stanley Chun-Wei Lee; Yijun Gao; Jean-Baptiste Micol; Patrick Campbell; Michael P Walsh; Brooke Sylvester; Igor Dolgalev; Olga Aminova; Adriana Heguy; Paul Zappile; Joy Nakitandwe; Chezi Ganzel; James D Dalton; David W Ellison; Juvianee Estrada-Veras; Mario Lacouture; William A Gahl; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Samuel R Briggs; Omotayo Fasan; Jared Block; Sebastien Héritier; Jean Donadieu; David B Solit; David M Hyman; José Baselga; Filip Janku; Barry S Taylor; Christopher Y Park; Zahir Amoura; Ahmet Dogan; Jean-Francois Emile; Neal Rosen; Tanja A Gruber; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2015-11-13       Impact factor: 39.397

8.  Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.

Authors:  Ankush Bhatia; Vaios Hatzoglou; Gary Ulaner; Raajit Rampal; David M Hyman; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Mariko Yabe; Kseniya Petrova-Drus; Katherine S Panageas; Anne Reiner; Marc Rosenblum; Eli L Diamond
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

9.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

10.  Neurological manifestations of Erdheim-Chester Disease.

Authors:  Louisa C Boyd; Kevin J O'Brien; Neval Ozkaya; Tanya Lehky; Avner Meoded; Bernadette R Gochuico; Fady Hannah-Shmouni; Avindra Nath; Camilo Toro; William A Gahl; Juvianee I Estrada-Veras; Rahul H Dave
Journal:  Ann Clin Transl Neurol       Date:  2020-03-29       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.